Ratings by Daiwa Securities (Narumi Nakagiri)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 5/14/2026 | Illumina | ILMN | Upgrade | Outperform (2) (Neutral (3)) |
145.70 (192.84) |
32.35% | Details | |
| 4/22/2026 | Abbott Labs | ABT | Downgrade | Neutral (3) (Outperform (2)) |
96.00 (109.72) |
14.29% | Details | |
| 2/12/2026 | Pfizer | PFE | Downgrade | Neutral (3) (Outperform (2)) |
27.61 (26.62) |
-3.59% | Details | |
| 12/16/2025 | Eli Lilly | LLY | Upgrade | Buy (1) (Neutral (3)) |
1027.51 (1215.02) |
18.25% | Details | |
| 10/20/2025 | Johnson & Johnson | JNJ | Upgrade | Outperform (2) (Neutral (3)) |
192.12 (259.80) |
35.23% | Details | |
| 8/18/2025 | Eli Lilly | LLY | Downgrade | Neutral (3) (Outperform (2)) |
701.23 (1027.51) |
46.53% | Details | |
| 8/12/2025 | Illumina | ILMN | Downgrade | Neutral (3) (Outperform (2)) |
94.56 (145.70) |
54.08% | Details | |
| 8/7/2025 | Abbvie | ABBV | Upgrade | Outperform (2) (Neutral (3)) |
198.55 (250.09) |
25.96% | Details | |
| 8/5/2025 | Bristol-Myers Squibb Co. | BMY | Downgrade | Neutral (3) (Outperform (2)) |
44.23 (63.61) |
43.82% | Details | |
| 12/5/2024 | Abbvie | ABBV | Downgrade | Neutral (3) (Buy (1)) |
176.46 (250.09) |
41.73% | Details | |
| 11/13/2024 | Bristol-Myers Squibb Co. | BMY | Upgrade | Outperform (2) (Neutral (3)) |
59.82 (63.61) |
6.34% | Details | |
| 11/11/2024 | Merck | MRK | Downgrade | Neutral (3) (Outperform (2)) |
102.92 (130.42) |
26.72% | Details | |
| 8/16/2024 | Illumina | ILMN | Upgrade | Buy (1) (Neutral (3)) |
122.28 (192.84) |
57.7% | Details | |
| 8/7/2024 | Pfizer | PFE | Upgrade | Outperform (2) (Neutral (3)) |
29.32 (26.62) |
-9.21% | Details | |
| 7/31/2024 | Edwards Lifesciences | EW | Upgrade | Outperform (2) (Neutral (3)) |
63.74 (93.66) |
46.94% | Details | |
| 7/23/2024 | Johnson & Johnson | JNJ | Downgrade | Neutral (3) (Outperform (2)) |
154.69 (259.80) |
67.95% | Details | |
| 12/21/2023 | Amgen | AMGN | Upgrade | Buy (1) (Neutral (3)) |
278.44 (414.30) |
48.79% | Details | |
| 11/2/2023 | Bristol-Myers Squibb Co. | BMY | Downgrade | Neutral (3) (Outperform (2)) |
51.53 (63.61) |
23.44% | Details | |
| 2/14/2023 | Merck | MRK | Maintain | Outperform (2) (N/A) |
|
Details | ||
| 8/12/2022 | Amgen | AMGN | Maintain | Buy (1) (N/A) |
|
Details | ||
| 7/6/2022 | Merck | MRK | Upgrade | Outperform (2) (Sell (5)) |
92.64 (130.42) |
40.78% | Details | |
| 5/6/2022 | Abbvie | ABBV | Downgrade | Sell (5) (Buy (1)) |
151.59 (250.09) |
64.98% | Details | |
| 12/16/2021 | Merck | MRK | New Coverage | Neutral (3) (N/A) |
73.72 (130.42) |
76.91% | Details | |
| 9/23/2021 | Amgen | AMGN | Downgrade | Neutral (3) (Outperform (2)) |
213.64 (414.30) |
93.92% | Details | |
| 8/5/2021 | Amgen | AMGN | Downgrade | Outperform (2) (Buy (1)) |
228.31 (414.30) |
81.46% | Details |
